AGL 37.84 Decreased By ▼ -0.16 (-0.42%)
AIRLINK 217.37 Increased By ▲ 3.46 (1.62%)
BOP 9.54 Increased By ▲ 0.12 (1.27%)
CNERGY 6.65 Increased By ▲ 0.36 (5.72%)
DCL 8.68 Decreased By ▼ -0.09 (-1.03%)
DFML 42.70 Increased By ▲ 0.49 (1.16%)
DGKC 95.20 Increased By ▲ 1.08 (1.15%)
FCCL 35.49 Increased By ▲ 0.30 (0.85%)
FFBL 88.94 No Change ▼ 0.00 (0%)
FFL 17.85 Increased By ▲ 1.46 (8.91%)
HUBC 127.56 Increased By ▲ 0.66 (0.52%)
HUMNL 13.87 Increased By ▲ 0.50 (3.74%)
KEL 5.42 Increased By ▲ 0.11 (2.07%)
KOSM 6.95 Increased By ▲ 0.01 (0.14%)
MLCF 43.55 Increased By ▲ 0.57 (1.33%)
NBP 59.67 Increased By ▲ 0.82 (1.39%)
OGDC 224.61 Increased By ▲ 5.19 (2.37%)
PAEL 41.06 Increased By ▲ 1.90 (4.85%)
PIBTL 8.27 Increased By ▲ 0.09 (1.1%)
PPL 196.45 Increased By ▲ 4.79 (2.5%)
PRL 38.90 Increased By ▲ 0.98 (2.58%)
PTC 27.50 Increased By ▲ 1.16 (4.4%)
SEARL 104.02 Increased By ▲ 0.02 (0.02%)
TELE 8.70 Increased By ▲ 0.31 (3.69%)
TOMCL 35.33 Increased By ▲ 0.58 (1.67%)
TPLP 13.94 Increased By ▲ 1.06 (8.23%)
TREET 25.45 Increased By ▲ 0.11 (0.43%)
TRG 72.20 Increased By ▲ 1.75 (2.48%)
UNITY 33.45 Increased By ▲ 0.06 (0.18%)
WTL 1.73 Increased By ▲ 0.01 (0.58%)
BR100 12,029 Increased By 134.6 (1.13%)
BR30 37,485 Increased By 630.4 (1.71%)
KSE100 111,671 Increased By 1247.5 (1.13%)
KSE30 35,136 Increased By 358.4 (1.03%)

European regulators adopted a new guideline on so-called biosimilar antibody drugs on Friday, paving the way for cheaper copies of multi-billion-dollar medicines used to treat cancer and other serious diseases. The new rules are keenly awaited by drug companies and investors, who want to know what level of clinical testing will be required to win approval in Europe for copies of complex antibody-based drugs.
Demands for extensive clinical studies in each disease area would push up the cost of developing biosimilar products. As expected, the European Medicines Agency (EMA) did not publish details of the planned new rules after they were endorsed at its monthly meeting of experts, but said they would be released on its website "shortly". A spokeswoman told Reuters earlier this week that publication could take a couple of weeks.
In a statement, the EMA merely said: "This guideline lays down the non-clinical and clinical requirements for monoclonal antibody-containing medicines claiming to be similar to another one already marketed."
Many industry experts expect a cautious approach, requiring separate clinical trials for different diseases addressed by the same antibody. That would be good news for original producers of monoclonal antibodies, such as Roche and Amgen. For makers of generic drugs, it would push up costs and might limit the field to a few sophisticated and well-funded companies such as Teva, which is working on biosimilars with Lonza; Novartis unit Sandoz; and Hospira.

Copyright Reuters, 2010

Comments

Comments are closed.